Research & products
We run to, not from, the world’s biggest health challenges.
The journey to invention and discovery is guided by science – and inspired by patients
Our purpose is to save and improve lives for generations. Our strategy is simple: We follow the science. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.
Our work in numbers
people employed in research and development
people reached through our major programs and partnerships
invested in R&D in 2019
We address the world’s most difficult health challenges, following world-class science
Discovery & development
Our progress is due in large part to the important and tough scientific questions we set out to answer with our trials and collaborations. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.
Our commitment to patients is unwavering
As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.
Invention begins here
Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccinesView our stories
Merck’s response to Ebola outbreaks
Along with international agencies and governments, Merck has played — and continues to play — a leadership role in responding to Ebola.Read more
Merck scientists probe how our bodies’ bugs impact immunity and disease
Our researchers are pioneering new ways to research and understand the biology of new diseases by looking inside the human gutDiscover how
Experts meet to discuss health care innovations during COVID
Merck’s chief patient officer, Julie Gerberding, joins the Fortune Global Forum to discuss breakthrough innovations in health careMore from Julie
Our third-quarter 2020 financial results
Merck announced third-quarter worldwide sales of $12.6 billion – an increase of 1% compared with the third quarter of 2019. Excluding the impact from foreign exchange, sales grew 2%. The company anticipates full-year 2020 revenue range to be between $47.6 billion and $48.6 billion, including a negative impact from foreign exchange of approximately 1.5%. Take […]Read more